Erythropoietin, a novel repurposed drug: An innovative treatment for wound healing in patients with diabetes mellitus

January 15, 2014

Saher Hamed et al. Wound Repair and Regeneration. Doi: 10.1111/wrr.12135

Recombinant erythropoietin (EPO) is a potential candidate for repurposing because the results of numerous studies have shown that systemic and topical EPO is therapeutically beneficial when it is administered to healthy and diabetic animals with acute and chronic skin wounds and burns.

Moreover, the molecular mechanisms of EPO's actions have been elucidated: EPO acts on those nonhematopoietic cells which are involved in the innate immune response where it promotes cellular proliferation and differentiation, exerts its cytoprotective actions, and inhibits apoptosis.

In this review, the mechanism of EPO's action in skin wound healing is reviewed, and its potential for treating acute and chronic skin wounds and stimulating tissue regeneration in diabetic patients is discussed.

Article information
Wound Repair and Regeneration
Jan 15, 2014
Free HCP newsletter
Join the newsletter
Free weekly news
Latest diabetes healthcare news direct to your inbox.
NHS employee:
Latest forum posts
The latest forum threads from the Ask a Question forum.
Healthcare Search